Evidence map›Paper›PMID 27194997›Full record

ArticleCardiorenal medicine2015

The Role of Congestion in Cardiorenal Syndrome Type 2: New Pathophysiological Insights into an Experimental Model of Heart Failure.

Annalisa Angelini, Chiara Castellani, Grazia Maria Virzì, Marny Fedrigo, Gaetano Thiene, Marialuisa Valente, Claudio Ronco, Giorgio Vescovo

Open access · bronzeAbstract read
In one paragraph

Article in Cardiorenal medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Small animal models of heart failure.Cardiovascular research · 2019
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Cellular apoptosis in the cardiorenal axis.Heart failure reviews · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Annalisa AngeliniDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua, Vicenza, Italy.
Chiara CastellaniDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua, Vicenza, Italy.
Grazia Maria VirzìDepartment of Nephrology, International Renal Research Institute Vicenza (IRRIV), Vicenza, Italy.
Marny FedrigoDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua, Vicenza, Italy.
Gaetano ThieneDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua, Vicenza, Italy.
Marialuisa ValenteDepartment of Cardiac, Thoracic and Vascular Sciences, University of Padua, Vicenza, Italy.
Claudio RoncoDepartment of Nephrology, International Renal Research Institute Vicenza (IRRIV), Vicenza, Italy.
Giorgio VescovoInternal Medicine Unit, Sant'Antonio Hospital Padua, Padua, Vicenza, Italy.
University of Padua · ITInternational Renal Research Institute of Vicenza · ITOspedale Sant Antonio · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn cardiorenal syndrome type 2 (CRS2), the role of systemic congestion in heart failure (HF) is still obscure. We studied a model of CRS2 [monocrotaline (MCT)-treated rats] secondary to pulmonary hypertension and right ventricular (RV) failure in order to evaluate the contribution of prevalent congestion to the development of kidney injury.

methodsTen animals were treated with MCT for 4 weeks until they developed HF. Eleven animals were taken as controls. Signs of hypertrophy and dilatation of the right ventricle demonstrated the occurrence of HF. Brain natriuretic peptide (BNP), serum creatinine (sCreatinine), both kidney and heart neutrophil gelatinase-associated lipocalin (NGAL), matrix metallopeptidase 9 (MMP9), serum cytokines as well as kidney and heart cell death, as assessed by TUNEL, were studied.

resultsRats with HF showed higher BNP levels [chronic HF (CHF) 4.8 ± 0.5 ng/ml; controls 1.5 ± 0.2 ng/ml; p < 0.0001], marked RV hypertrophy and dilatation (RV mass/RV volume: CHF 1.46 ± 0.31, controls 2.41 ± 0.81; p < 0.01) as well as pleural and peritoneal effusions. A significant increase in proinflammatory cytokines and sCreatinine was observed (CHF 3.06 ± 1.3 pg/ml vs. controls 0.54 ± 0.23 pg/ml; p = 0.04). Serum (CHF 562.7 ± 93.34 ng/ml vs. controls 245.3 ± 58.19 ng/ml; p = 0.02) as well as renal and heart tissue NGAL levels [CHF 70,680 ± 4,337 arbitrary units (AU) vs. controls 32,120 ± 4,961 AU; p = 0.001] rose significantly, and they were found to be complexed with MMP9 in CHF rats. A higher number of kidney TUNEL-positive tubular cells was also detected (CHF 114.01 ± 45.93 vs. controls 16.36 ± 11.60 cells/mm(2); p = 0.0004).

conclusionIn this model of CHF with prevalent congestion, kidney injury is characterized by tubular damage and systemic inflammation. The upregulated NGAL complexed with MMP9 perpetuates the vicious circle of kidney/heart damage by enhancing the enzymatic activity of MMP9 with extracellular matrix degradation, worsening heart remodeling.

Indexed as

Cardiorenal syndromesCytokinesHeart failureKidney injuryMatrix metallopeptidase 9Neutrophil gelatinase-associated lipocalin

Identifiers

PMID27194997
PMCPMC4698640
OpenAlexW2265202306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.